Journal: Retrovirology

Article Title: Extracellular vesicles from HTLV-1 infected cells modulate target cells and viral spread

doi: 10.1186/s12977-021-00550-8

Figure Lengend Snippet: Functional Effects of HTLV-1 EVs on Angiogenesis and Inflammation. a An angiogenesis assay in technical and biological triplicate was used to determine the effect of distinct HTLV-1 EVs (2 k, 10 k, and 100 k) on tubular formation in a co-culture of mesenchymal stem cells (MSCs) and aortic endothelial cells (AEC). EV-treated cells (1:2000 recipient cell to EV ratio). Positive control cells received complete, undiluted medium. Additional dose of EV treatment was given to the cells at day 4. Representative images were taken at days 3 and 6 showing tubular formation in response to the indicated treatment. b The image processing software WIMASIS was used to calculate the percentage of area covered by tubules (n = 3) on day 3 and day 6. c RT-qPCR results showing env RNA copy numbers of mesenchymal stem cells treated with CEM EVs (control) and different populations of HTLV-1 EVs: 2 k (left panel), 10 k (middle panel), and 100 k (right panel). A set of dashed black vertical lines (---) were used to indicate baseline env RNA copy numbers. A set of dashed red vertical lines ( ) were used to indicate the levels of starting material, suggestive of the minimum env RNA copy numbers necessary for EVs to increase vial spread in MSc. d Western blot analysis for core histones (H3, H2A, H2B, and H4), linker histone (H1) and actin in HUT102 EVs (2 k, 10 k, and 100 k). e GAPDH DNA levels (representative of nucleosomes) in 2 k, 10 k, and 100 k HUT102 EVs treated with proteinase K and DNase/RNase were evaluated by was quantitated by q-PCR. A two-tailed student t-test was used to evaluate statistical significance with “**” for p-values ≤ 0.01, indicating the level of significance relative to untreated (Control) samples

Article Snippet: Bone marrow derived Mesenchymal Stem Cells (MSCs) were cultured in Mesenchymal Stem Cell Basal Medium (ATCC PCS-500–030TM) supplemented with Mesenchymal Stem Cell Growth Kit for Bone Marrow-derived MSCs (ATCC PCS-500-041TM).

Techniques: Functional Assay, Angiogenesis Assay, Co-Culture Assay, Positive Control, Software, Quantitative RT-PCR, Control, Western Blot, Two Tailed Test

Journal: Korean Journal of Neurotrauma

Article Title: Evaluation of Bone Marrow-derived Stem Cells and Adipose-derived Stem Cells Co-cultured on Human Nucleus Pulposus Cells: A Pilot Study

doi: 10.13004/kjnt.2020.16.e36

Figure Lengend Snippet: SA-β-gal: senescence associated-β-gal, NP: nucleus pulposus, NPC: nucleus pulposus cell, MSC: mesenchymal stem cell, ADMSC: adipose-derived mesenchymal stem cell, BDMSC: bone marrow-derived mesenchymal stem cell.

Article Snippet: BDMSC complete culture medium (ATCC ® PCS-500-030) plus one MSC growth kit (ATCC ® PCS-500-041) and ADMSC complete culture medium (ATCC ® PCS-500-030) plus one MSC growth kit (ATCC ® PCS-500-040) were used to cultivate both MSCs; this medium consists of 485 mL Human MSC Basal Medium, 35 mL Human MSC-Qualified FBS, 0.5 mL penicillin/streptomycin-amphotericin and 6 mL L-alanyl-L-glutamine.

Techniques: Derivative Assay

Journal: Biomedicines

Article Title: Extracellular Vesicles from Mesenchymal Stem Cells: Potential as Therapeutics in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

doi: 10.3390/biomedicines12122848

Figure Lengend Snippet: MSC-EV therapy in rodent models of MASH/NASH.

Article Snippet: Rats Bone marrow MSCs , Sprague Dawley (SD) rat , HFD for 12 weeks , Suppressed steatosis, reduced hepatocyte ballooning, AST, ALT, and expression of SREBP-1, SREBP-2, ACC, CD36, decreased NAS, increased expression of PPARα and CPT1. Suppression of caspase 2, apoptosis, mitophagy , 15, 30, 120 μg/kg i.v. Twice a week starting on week 7 for 6 weeks , [ ] .

Techniques: Clinical Proteomics, Expressing, Injection, Gene Expression, Western Blot

Journal: International Journal of Nanomedicine

Article Title: Drug Delivery to the Bone Microenvironment Mediated by Exosomes: An Axiom or Enigma

doi: 10.2147/IJN.S307843

Figure Lengend Snippet: Patents Related to the Diagnostic and Therapeutic Application of Exosomes Towards Bone Disorders

Article Snippet: Bone marrow-derived mesenchymal stem cells (BM-MSCs) and Adipose-derived stem cells (ASCs) , WO2019139762A1 , Zen-Bio, Inc. (US) , Exosome compositions and use thereof for joint disorders and diseases , Filed on 2018/Status pending.

Techniques: Diagnostic Assay, Biomarker Discovery, Derivative Assay, CRISPR, Isolation, Injection, Clinical Proteomics